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Peripheral administration of the soluble TNF inhibitor XPro1595 
modifies brain immune cell profiles, decreases beta-amyloid 
plaque load, and rescues impaired long-term potentiation in 
5xFAD mice
Kathryn P. MacPhersona, Pradoldej Sompolb, George T. Kannarkata, Jianjun Changa, 
Lindsey Sniffena, Mary E. Wildnera, Christopher M. Norrisb, and Malú G. Tanseya,*
aEmory University School of Medicine, 30322, United States
bSanders-Brown Center on Aging, University of Kentucky College of Medicine, Lexington, KY 
40536, United States
Abstract
Clinical and animal model studies have implicated inflammation and peripheral immune cell 
responses in the pathophysiology of Alzheimer’s disease (AD). Peripheral immune cells including 
T cells circulate in the cerebrospinal fluid (CSF) of healthy adults and are found in the brains of 
AD patients and AD rodent models. Blocking entry of peripheral macrophages into the CNS was 
reported to increase amyloid burden in an AD mouse model. To assess inflammation in the 5xFAD 
(Tg) mouse model, we first quantified central and immune cell profiles in the deep cervical lymph 
nodes and spleen. In the brains of Tg mice, activated (MHCII+, CD45high, and Ly6Chigh) myeloid-
derived CD11b+ immune cells are decreased while CD3+ T cells are increased as a function of age 
relative to non-Tg mice. These immunological changes along with evidence of increased mRNA 
levels for several cytokines suggest that immune regulation and trafficking patterns are altered in 
Tg mice. Levels of soluble Tumor Necrosis Factor (sTNF) modulate blood-brain barrier (BBB) 
permeability and are increased in CSF and brain parenchyma post-mortem in AD subjects and Tg 
mice. We report here that in vivo peripheral administration of XPro1595, a novel biologic that 
sequesters sTNF into inactive heterotrimers, reduced the age-dependent increase in activated 
immune cells in Tg mice, while decreasing the overall number of CD4+ T cells. In addition, 
XPro1595 treatment in vivo rescued impaired long-term potentiation (LTP) measured in brain 
slices in association with decreased Aβ plaques in the subiculum. Selective targeting of sTNF may 
modulate brain immune cell infiltration, and prevent or delay neuronal dysfunction in AD.
Significance statement—Immune cells and cytokines perform specialized functions inside and 
outside the brain to maintain optimal brain health; but the extent to which their activities change in 
response to neuronal dysfunction and degeneration is not well understood. Our findings indicate 
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that neutralization of sTNF reduced the age-dependent increase in activated immune cells in Tg 
mice, while decreasing the overall number of CD4+ Tcells. In addition, impaired long-term 
potentiation (LTP) was rescued by XPro1595 in association with decreased hippocampal Aβ 
plaques. Selective targeting of sTNF holds translational potential to modulate brain immune cell 
infiltration, dampen neuroinflammation, and prevent or delay neuronal dysfunction in AD.
Keywords
Neuroinflammation; Alzheimer’s disease; Immune cell trafficking; T cells; Macrophage; MHCII; 
Soluble TNF; Long-term potentiation; XPro1595
1. Introduction
Inflammation as a hallmark of Alzheimer’s disease (AD) is well established. However, the 
mechanisms by which the peripheral immune system contributes to the etiology or 
progression of AD are not yet elucidated. The pro-inflammatory response of brain-resident 
immune cells to AD pathophysiology leads to increased local production of cytokines and 
chemokines, and recruitment of peripheral immune cells (Akiyama et al., 2000; Heneka et 
al., 2015). The chemoattractant CCL2/MCP-1, plays an important role in recruitment of 
phagocytic macrophages to the inflamed CNS (Hickman and El Khoury, 2010), and is 
upregulated in CSF, but not plasma, of MCI and early stage AD patients (Brosseron et al., 
2014). These observations suggest peripheral immune cells respond to signals generated in 
the CNS and traffic across the blood brain barrier (BBB) to play an important role in early 
AD. T cells are also found in increasing frequency in postmortem brain of aged individuals 
and patients with AD (Togo et al., 2002). Recently identified lymphatic vessels in the rodent 
brain regulate neuroimmune responses by connecting to deep cervical lymph nodes 
(DCLNs) where they drain antigens from the brain parenchyma (Ransohoff and Engelhardt, 
2012; Laman and Weller, 2013; Aspelund et al., 2015; Louveau et al., 2015). The extent to 
which alterations in immune cell trafficking to the brain occur during the course of AD and 
whether these are beneficial or maladaptive remains unknown.
At the pinnacle of inflammatory cascades, elevations in TNF are associated not only with 
induction of the inflammatory response but also with chronic inflammation (MacEwan, 
2002; Steinman, 2013). TNF exists in two functional forms: soluble TNF (sTNF) and 
transmembrane TNF (tmTNF), each with distinct functional bioactivities. sTNF signaling, 
primarily via TNFR1, results in pro-inflammatory actions while tmTNF signaling, primarily 
via TNFR2 results in pro-survival signaling and plays an important role in immune system 
development (McCoy and Tansey, 2008). TNF elevations are reported in AD patient plasma, 
and an acute increase in serum TNF, as well as higher baseline TNF level, has been 
associated with greater cognitive decline in elderly populations (Holmes et al., 2009; 
Swardfager et al., 2010). Results from non-selective TNF blockade in pre-clinical animal 
models of AD-like pathology call into question the validity of the therapeutic benefit of 
targeting TNF in AD (Montgomery et al., 2011); however studies specifically targeting 
sTNF/TNFR1 axis in the CNS are promising (McAlpine et al., 2009). Neuronal ablation of 
TNFR2, but not TNFR1, increased extracellular Aβ (Montgomery et al., 2013), a hallmark 
of AD pathology, while ablation of TNFR1 increased Iba1 (microglial) reactivity in the 
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hippocampus of 12-month old 3xTg-AD mice (Montgomery et al., 2013), a potentially 
beneficial response as microglia have a complex role in brain health and disease 
(Mandrekar-Colucci and Landreth, 2010). Together, these data provide rationale for the 
specific targeting of sTNF while sparing tmTNF/TNFR2 signaling. Moreover, loss of BBB 
integrity establishes an environment susceptible to dysregulated interactions with the 
peripheral immune system. TNF downregulates the BBB phenotype in human brain 
microvascular endothelial cells at 1 ng/mL TNF (Rochfort et al., 2014). While plasma and 
CSF TNF levels in AD patients are typically 10 fold lower than this, the permeability of the 
BBB increases as a function of age and these sTNF levels may be sufficient for further BBB 
disruption in subjects with MCI, promoting faster conversion to AD (Swardfager et al., 
2010; Montagne et al., 2015).
Here, we measure populations of peripheral immune cells found in the CNS of 5xFAD (Tg) 
mice and assess the role of sTNF in recruiting these populations to the brain. We 
investigated whether inhibition of sTNF, with XPro1595 (Steed et al., 2003; McCoy et al., 
2006; Brambilla et al., 2011) would mitigate the AD-like pathology found in Tg mice and 
evaluated the extent to which these effects occur in association with alterations in central and 
peripheral immune cell population profiles. Our results showed that neutralization of sTNF 
reduces proinflammatory immune cell markers and gene expression, and rescues impaired 
LTP within the Tg brain.
2. Methods
2.1. Animals
The 5xFAD (Tg) mouse model displays key pathological hallmarks of AD including 
synaptic dysfunction, plaque accumulations, and neuronal degeneration (Oakley et al., 
2006). While amyloid deposition begins early in this model, around 2 months, spatial 
working memory deficits in Y-maze are not detected until 4–5 months of age (Oakley et al., 
2006). Our own group has not found significant deficits in 8-arm radial water maze until 8–
10 months (unpublished observations). Female 5xFAD mice, on a congenic C57BL/6J 
background, were used for all flow cytometry, XPro1595, and electrophysiology 
experiments to assess the role of sTNF and trafficking immune cell populations in AD-like 
pathology. Female mice were used because they show accelerated AD-like pathology when 
compared to male 5xFAD mice (Oakley et al., 2006). For all XPro1595 studies mice were 
randomly assigned to treatment group based on genotype, and investigators involved in 
quantification of outcome measures were blinded to genotype and treatment history. For 
measurements of cytokines in CSF by multiplexed immunoassay and inflammatory mRNA 
analysis by qPCR, we used both male and female mice at 2-, 4-, and 6-months of age to 
assess baseline level of inflammation in the periphery and within the brain, Table 1. 
Specifics on age and group size are detailed in each specific methods section. Tg mice, 
generously provided by Vassar lab, were co-housed in a vivarium at Emory University, or 
University of Kentucky for electrophysiology studies, with ad libitum access to food and 
water on a 12 h light/dark cycle. All experimental procedures were approved by the 
Institutional Animal Care and Use Committee of Emory University or University of 
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Kentucky and comply with the National Institutes of Health guide for the care and use of 
Laboratory animals.
2.2. Multiplexed immunoassays
Serum and CSF samples were analyzed for cytokines and chemokines that play key roles in 
pro-inflammatory and anti-inflammatory pathways (IFN-γ,IL-1β, IL-6, IL-10, IL-12p70, 
mKC/CXCL1, and TNF) using a V-PLEX multiplexed immunoassay per the manufacturer’s 
instructions (Meso Scale Discovery, Gaithersburg, MD). XPro1595 levels in serum and brain 
were measured using an anti-human TNF ultrasensitive (Cat # K151BHC-1) singleplex 
immunoassay and quantified using the Meso Scale Discovery SECTOR Imager 2400-A 
(Meso Scale Diagnostics, LLC, Rockville, MD). To measure XPro1595, the supplied human 
TNF protein used to generate a calibrator/standard protein was replaced by the XPro1595 
protein, which increases the sensitivity of the assay substantially. Signals from the linear 
standard curve range from 3000 (at 0 XPro1595) to 1 million counts (at 250 ng/mL). All 
samples were assayed in duplicate by an experimentalist blinded to treatment history. The 
data were analyzed and converted to pg/mL values using the Meso Scale Discovery 
integrated data analysis software. Mice used: 2 months of age Tg: 4 male and 3 female 
samples pooled −30 μL total; non-Tg: 1 male and 7 female samples pooled −20 μL total; 4 
months of age Tg: 2 male and 3 female samples pooled −20 μL total; non-Tg: 5 male and 3 
female samples pooled − 50 μL total; 6 months of age Tg: 5 male and 3 female samples 
pooled −30 μL total; non-Tg: 3 male and 2 female samples pooled −40 μL total. Samples 
were run in replicates of 10 μL. Samples were pooled for analysis of CSF cytokines and 
chemokines due to the very low volume yield per animal.
2.3. Brain dissociation for immune cell isolation
5xFAD mice were anesthetized with isoflurane and whole brain, deep cervical lymph nodes, 
and spleen were removed. Rapid removal of the brain ensured high immune cell yield and 
viability needed to run two multi-channel flow panels on the harvested immune cells. In 
pilot studies, we compared the yield, viability, and brain immune subset frequencies between 
perfused and non-perfused mice and confirmed that this method of harvest did not result in 
contamination from blood vessels as there were no differences across the non-brain tissues 
(spleen and deep cervical lymph nodes) in CD4+ and CD8+ T cell subsets, or in the number 
of viable cells (data not shown). More importantly, we found no significant differences in the 
frequency of total CD3+ T cell or within the CD4+ and CD8+ T cell subset populations in the 
brains of non-perfused as compared to perfused mice. Given that the frequency of T cell 
populations is much higher in the blood than in the brain, contamination from blood PBMC 
populations would have resulted in an increase in the frequency of T cells in non-perfused 
animals as compared to perfused animals. Whole brain tissue was finely minced in 1xHBSS 
(without Calcium, Magnesium, and phenol red, Invitrogen, 14175) and transferred to an 
enzymatic DDP solution (DMEM/F12 media containing 1 mg/mL papain from papaya latex 
(P4762 Sigma Aldrich, St. Louis, MO), 1.2 U/mL dispase II (4942078001 Roche 
diagnostics, Risch-Rotkreuz, Switzerland), and 220 U/mL DNAse I (18047-019 Invitrogen, 
Carlsbad, CA)). The minced tissue and DDP was incubated at 37 °C for 20 min before being 
neutralized with 10% FBS (heat inactivated, Atlanta Biologicals, S11150). The tissue pellet 
was homogenized in ice-cold 1xHBSS using a fine-tip glass pipette. The homogenate was 
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filtered through a 70 μM cell strainer. The pellet was resuspended in 37% Percoll (Percoll 
pH 8.5–9.5; Sigma Aldrich Co, P1644) and 70% Percoll layered below, and 30% Percoll 
layered above, with 1xHBSS layered on the top. The Percoll gradient was centrifuged and 
immune cells were collected from the cell cloud between the 70% and 37% Percoll layer, 
washed with 4× volume of 1xHBSS. Cells were split in half and stained with separate 
antibody panels for flow cytometry; approximately 1 × 106 cells were used per panel.
2.4. Spleen dissociation for immune cell isolation
The spleen was removed and placed into 1xHBSS with 5% FBS. A single cell solution was 
made by passing tissue through a 70 μM cell strainer. Cells were counted on a 
hemocytometer at a 1 to 10 dilution, and 1 ×106 cells were stained per animal.
2.5. Deep cervical lymph node dissociation for immune cell isolation
Both the right and left deep cervical lymph nodes were removed and placed into 1xHBSS 
with 5% FBS. A single cell solution was made by passing tissue through a 70 μM cell 
strainer. Cells were counted on a hemocytometer at a 1 to 1 dilution, and 1 × 106 cells were 
stained per animal.
2.6. Multi-color flow cytometry
All cells were stained with Live/Dead Fixable Aqua (1:2000, L34957 Invitrogen) and 
incubated with anti-mouse CD16/CD32 (1:100, 140161085 eBioscience). 1 × 106 cells from 
the spleen, deep cervical lymph nodes, and brain were stained with panel 1: anti-mouse CD3 
PE eFluor 610 (1:100, 61-0031 eBioscience), anti-mouse CD4 Alexa Fluor 488 (1:100, 
53-0041 eBioscience), anti-mouse CD8b APC-eFluor780 (1:100, 47-0083 eBioscience), 
anti-mouse CD62L PE-Cy7 (1:200, 25-0621 eBioscience), anti-mouse CD44 Alexa Fluor 
700 (1:00, 130326 BioLegend) in FACS buffer. One million cells from the brain were 
stained with panel 2: anti-mouse Ly6G PacBlue (1:100,127611 BioLegend), anti-mouse 
CD11b FITC (1:100, 11-0112 eBioscience), anti-mouse CD19 PE (1:100, 561736 BD 
Bioscience), anti-mouse MHCII Pe-Cy7 (1:100, 25-5321 eBioscience), anti-mouse CD45 
PerCP-Cy5.5 (1:100, 45-0451 eBioscience), anti-mouse CD3 PE eFluor610 (1:100, 61-0031 
eBioscience), anti-mouse CD11c Alexa Fluor 700 (1:50,117320 BioLegend), anti-mouse 
Ly6C APC-Cy7 (1:100,128026 BioLegend) in FACS buffer. Samples were run on an LSRII 
(BD Biosciences) and analyzed with FlowJo_V10.
Single cell lymphocytes were gated based on forward scatter height (FSH) (size) and Side 
Scatter Height (SSH) (granularity) and then by FSH by FHA (forward scatter area). Live 
cells were then selected as the Fixable Aqua negative population. In the samples stained with 
panel 1: CD3+ cells were selected and then gated for CD4+ and CD8+. Each of the CD4+ 
and CD8+ gated populations were gated by CD44 vs CD62L. In samples stained with panel 
2: CD45+ cells were selected and then gated by CD3 (T cells) vs Ly6G (Neutrophils). The 
CD3−Ly6G− population was gated CD19 vs CD11b and the CD11b+CD19− population was 
gated for CD45high and CD45low populations. Those populations were gated for MHCII+ 
and MHCII− and Ly6Chigh and Ly6clow from histogram distribution. The CD11b+CD19− 
population was also gated for CD11c, a marker of dendritic cells and potentially of a 
subpopulation of antigen presenting microglia (Wlodarczyk et al., 2014). From every sample 
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counting beads (AccuCheck Counting Beads, Invitrogen PCB100, 10 μL were added to each 
sample before running on the LSRII) were selected on size from the FSH vs FHA plot and 
then again from FSH vs FHA. Sample counts of all target populations were calculated in 
FlowJo and from these counts total tissue counts were obtained: ((population count/bead 
count) × bead concentration in sample run) × run volume × (whole sample volume/volume 
processed for 1 × 106 cells).
For assessment of immune cells populations at 3.5, 5, 7, and 12 months the following group 
sizes of female 5xFAD were used: 3.5 months: non-Tg n = 8, Tg n = 9; 5 months: non-Tg n 
= 11, Tg n = 11; 7 months: non-Tg n = 11, Tg n = 13; 12 months: non-Tg n = 10, Tg n = 9. 
Within these groups, subsets with robust MHCII and Ly6C staining were used for analysis of 
these markers in the brain, non-robust staining was determined as antibody or experimental 
error and not specific to treatment group or genotype: 3.5 months: non-Tg n = 8 (MHCII)/5 
(Ly6C), Tg n = 9/4; 5 months: non-Tg n = 4/7, Tg n = 7/8; 7 months: non-Tg n = 8/6, Tg n = 
11/7; 12 months: non-Tg n = 9/10, Tg n = 8/4. From the overall group, a subset of samples 
had robust CD44 and CD62L staining and were used for analyses of those markers in brain 
3.5 months non-Tg n = 5, Tg n = 3; 5 months: non-Tg n = 4, Tg n = 4; 7 months: non-Tg n = 
5, Tg n = 5; 12 months: non-Tg n = 6, Tg n = 4.
2.7. XPro1595 administration
XPro1595 is a PEG-ylated human TNF variant devoid of TNF receptor-binding activity that 
forms heterotrimers with native sTNF (but not membrane-bound TNF), thereby sequestering 
sTNF away from TNF receptors (Steed et al., 2003; Barnum et al., 2014). To assess the role 
of sTNF in AD-like pathology and immune cell trafficking to the CNS, Tg female mice were 
divide into two cohorts each with two treatment groups. Mice received either subcutaneous 
(s.c.) saline vehicle control or s.c. XPro1595 (10 mg/kg) twice weekly for two months. This 
dose was selected on the basis of PK/PD studies and its efficacy in reducing dopaminergic 
neuron loss and glial activation in a rat model of nigral degeneration (Barnum et al., 2014). 
When administered peripherally, XPro1595 is detectable in the brain (1 and 6 ng/mL of is 
detectable in the brain (Supp Fig. S1) which is sufficient to neutralize the native soluble 
homotrimer TNF through soluble heterotrimer formation; To assess the role of sTNF on 
trafficking immune cell population one cohort of female mice was treated between 5 and 7 
months of age (Saline n = 9, XPro1595 n = 10); within this group, n = 9 saline and n = 7 
XPro1595 were used for analysis of the Ly6C marker within the myeloid panel, and n = 5 
saline and n = 6 XPro1595 were used for analysis of CNS T cell panel in addition to the 
CNS myeloid panel). The other cohort was treated with XPro1595 or saline between 2 and 4 
months of age (Saline n = 8 and XPro1595 n = 7). XPro1595 (generously provided by Dr. 
David Szymkowski at Xencor, Inc.) was diluted with sterile saline to 2 mg/mL concentration 
to be dosed in mice at 10 mg/kg. To assess the role of sTNF on AD-like amyloid 
accumulation and mRNA associated with inflammatory markers female Tg and non-Tg mice 
treated with either saline or XPro1595 from 5 to 7 months of age (non-Tg saline n = 8, non-
Tg XPro1595 n = 6, Tg saline n = 3, Tg XPro1595 n = 5).
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2.8. Electrophysiology
Brain slice electrophysiology methods were performed as previously published (Mathis et 
al., 2011; Bachstetter et al., 2012; Furman et al., 2012). The study design was the same as 
for the mice used for immunological and histological outcome measures. After eight weeks 
of i.p. injections, mice were deeply anesthetized with CO2 and decapitated. Brains were 
removed and stored briefly in ice-cold, Ca2+-free artificial cerebrospinal fluid (ACSF) 
containing (in mM) 124 NaCl, 2 KCl, 1.25 KH2PO4, 2 MgSO4, 26 NaHCO3,10 dextrose 
(pH = 7.4), and saturated with 95% O2 and 5% CO2.400 μm-thick sections were cut on a 
Vibratome® 1000 vibrating microtome (Leica Biosystems, Buffalo Grove, IL). Slices were 
then transferred to a custom holding chamber (Mathis et al., 2011) and maintained in CaCl2-
containing (2 mM)-ACSF at an interface with warm (32 °C), humidified air. Slices were 
permitted to equilibrate for at least 1.5 h before beginning electrophysiological analysis. 
Investigators were blinded to treatment history.
Slices were transferred to an RC-27 recording chamber (Warner Instruments, Hamden, CT) 
and perfused with oxygenated ACSF (32 °C) at a rate of 1–2 mL/min for 15–20 min before 
the start of each recording session. CA3 Schaffer collaterals were activated with a bipolar 
platinum-iridium electrode located in stratum radiatum near the CA3 border. Stimulus 
intensity was controlled by a constant current stimulus isolation unit (World Precision 
Instruments, Sarasota, FL), and stimulus timing was controlled by Clampex 9.2 software 
(Molecular Devices, Sunnyvale, CA). Field EPSPs were recorded using a glass micropipette 
(1–6 MΩ), filled with ACSF and containing an Ag-AgCl wire, positioned in stratum 
radiatum of CA1, approximately 1–2 mm away from the point of stimulation. Field 
potentials were amplified 100 ×, Bessel-filtered at 1 kHz, and digitized at 10 kHz using a 
Multiclamp 700B amplifier and a Digidata 1320 digitizer (Molecular Devices).
To assess basal synaptic strength, twin stimulus pulses (S1 and S2, 100 μs pulse duration, 50 
ms interpulse interval) were given at 12 intensity levels (range 25–500 μA) at a rate of 0.1 
Hz. Five field potentials at each level were averaged, and measurements of fiber volley (FV) 
amplitude (in mV) and excitatory postsynaptic potential (EPSP) slope (mV/ms) for S1 were 
performed offline using ClampFit software (Molecular Devices). Synaptic strength curves 
were constructed by plotting the EPSP slope against the FV amplitude at each stimulus 
intensity. Maximal synaptic strength for each slice was estimated by taking the maximal 
EPSP slope amplitude during the input/output curve and dividing by the corresponding FV 
amplitude. Paired-pulse facilitation (PPF) was calculated by dividing the S2 EPSP slope by 
the S1 EPSP (taken from the linear portion of the synaptic strength curve) and multiplying 
by 100. To estimate population spike (PS) threshold, the EPSP slope amplitude at which a 
population spike first appeared in the ascending phase of the field potential was calculated 
and averaged across five successive trials at the spike threshold stimulation level.
After synaptic strength curves were constructed, the stimulus intensity was readjusted to 
elicit an EPSP of ~1 mV, and stimulus pulses were delivered at 0.033 Hz until a stable 20 
min baseline was established. High-frequency stimulation (two 100 Hz trains, 1 s each, 10 s 
intertrain interval) was then delivered at the baseline stimulation intensity to induce LTP, 
followed by an additional 60 min baseline. Within each group, EPSP slope measures from 
the last 10 min of the post-LTP baseline were averaged across slices within each animal and 
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compared to the pre-LTP baseline slope average. Electrophysiological parameters were 
averaged across all slices within each animal (one to three slices), and the n used for 
statistical comparisons reflects the number of animals per genotype and treatment group.
2.9. Brain dissection for RNA extraction
Mice were rapidly decapitated under isoflurane and the brain was removed. Half of the brain 
was post fixed for immunohistochemistry (see below). From the other half, the cerebellum, 
midbrain, hippocampus, and cortex were dissected out on a cold glass petri dish. Tissue was 
fast cooled in liquid nitrogen and stored at −80C° until processing. Tissue was processed by 
first homogenizing in Trizol (Life Technologies, 1596018) with a Tissue LyserII (Retsch). 
mRNA was isolated with RNeasy kit (Qiagen, 74106) and treated with DNAase1 
(Invitrogen, 18068).
2.10. Real-time PCR (qPCR)
To assess baseline inflammation at 2,4 and 6 months of age, tissue was collected from the 
same mice used for the CSF collection (2 months: Tg 4 Male and 4 Female, non-Tg 5 Male 
and 9 Female; 4 months: Tg 4 Male and 6 Female, non-Tg 6 Male and 4 Female; 6 months: 
Tg 3 Male and 4 Female, non-Tg 7 Male and 7 Female) and assessed for expression of 
mRNA associated with pro-inflammatory cytokines. To assess hippo-campal inflammation 
and the role of sTNF tissue was collected from female Tg and non-Tg mice treated with 
either saline or XPro1595 from 5 to 7 months of age (non-Tg saline n = 8, non-Tg XPro1595 
n = 6, Tg saline n = 3, Tg XPro1595 n = 5), only half of the brain was use the other half was 
post fixed for immunohistochemistry, below. Power analysis (75%) to determine significant 
effect of TNF mRNA in hippocampus due to genotype (Tg mean = 5.390, non-Tg mean = 
1.103, SD = 1.992) determined a samples size =3 is sufficient.
Reverse transcription was preformed to make cDNA as published previously (Kannarkat et 
al., 2015). Briefly, cDNA was used with the following primer sets for qPCR, with TATA 
binding protein used as a housekeeping control to normalize samples: TNF - Forward 5′ 
CTG AGG TCA ATC TGC CCA AGT AC 3′ Reverse 5′ CTT CAC AGA GCA ATG ACT 
CCA AAG 3′; CCL2 - Forward 5′ CTT CCT CCA CCA CCA TGC A 3′ Reverse 5′ CCA 
GCC GGC AAC TGT GA 3′; TGFβ - Forward 5′ GCA GTG GCT GAA CCA AGG A 3′ 
Reverse 5′ AGA GCA GTG AGC GCT GAA TC 3′;IL-1β - Forward 5′ CAA CCA ACA 
AGT GAT ATT CTC CAT G 3′ Reverse 5′ GAT CCA CAC TCT CCA GCT GCA 3′; 
TATA binding protein - Forward 5′ GTA TCT GCT GGC GGT TTG G 3′ Reverse 5′ GGC 
ACT GCG GAG AAA ATG A 3′; CD45 - Forward 5′ TCA TGG TCA CAC GAT GTG 
AAG A 3′ Reverse 5′AGC CCG AGT GCC TTCCT3′;TNFR1 - Forward 5′ GTC CAT 
TCT AAG AAC AAT TCC ATC TG 3′ Reverse 5′GCT CGG ACA GTC ACT CAC CAA 
3′;TNFR2 - Forward 5′ CTA TGA CAG GAA GGC TCA GAT GTG 3′ Reverse 5′GTG 
TCC GAG GTC TTG TTG CA 3′;IFNγR - Forward 5′ GAC GTC TGT ATC CCT CCT 
TTC C 3′ Reverse 5′ GTA AGA GGA GCA ACC ACC AGA A 3′.
2.11. Brain dissociation for immunohistochemistry and histological analysis
Female Tg and Non-Tg mice treated with XPro1595 or saline from 5 to 7 months of age 
(non-Tg saline n = 8, non-Tg XPro1595 n = 6, Tg saline n = 3, Tg XPro1595 n = 5) were 
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rapidly decapitated under isoflurane and the brain was removed. Half of the brain was post 
fixed for immunohistochemistry in 4% PFA for 24 h and then transferred to 30% sucrose in 
1xPBS. Brains (n = 4 per treatment group) were embedded and sectioned at 35 μM; serial 
sections were stained with anti-Amyloid-β (6e10), counterstained with thionine, and Amino 
Cupric Silver staining for to measure disintegration of multiple neuronal elements including 
cell bodies, axons, dendrites, and synaptic terminals, and counterstained with Nissl red by 
NeuroScience Associates (Knoxville, TN). Slides were scanned using the Aperio System 
(Leica Biosystems). Regions of interest were outlined and analyzed in ImageScope (Leica 
Biosystems). Sections stained with 6e10 were analyzed with the algorithm (positive pixel 
count), positive and strong positive pixels were used to measure amyloid density. Sections 
stained with amino cupric silver were analyzed with a modified algorithm with the following 
settings: Hue value 0.1, Hue width 0.8, CST 0.04, Iwp (high) 200, Iwp (low) 175, Ip (low) 
110, Isp (low) 0, Inp (high) −0.8. Only strong positive pixels were used to measure early 
cellular degradation.
2.12. Statistical analysis
Synaptic strength parameters and LTP values were compared across genotypes and drug 
treatment conditions with two-way analysis of variance (ANOVA) using GraphPad Prism 6 
software (La Jolla, CA). Fisher’s PLSD was used for post hoc comparisons. Cytokine 
protein values from multiplexed immunoassay analyses were compared across genotypes 
with in each age using non-parametric t-test using GraphPad Prism 6 software. qPCR data 
for aging evaluation of inflammatory mRNA data was normalized to 2mo non-Tg and were 
compared across genotypes and age with two-way ANOVA. Sidak’s multiple comparisons 
test was used for post hoc comparisons within each age. Data from immunophenotyping 
studies across age was compared across genotypes and age with two-way ANOVA. Sidak’s 
multiple comparisons test was used for post hoc comparisons within each age. Effects of 
XPro1595 on Tg immune cell populations, 6E10, and immune cupric Ag reactivity were 
determined across treatment using non-parametric t-test using GraphPad Prism 6 software. 
XPro1595 effects on mRNA expression were normalized to non-tg saline and analyzed 
across genotypes and drug treatment conditions with two-way ANOVA. Sidak’s multiple 
comparisons test was used for post hoc comparisons within genotype. Significance for all 
statistical comparisons was set at p ≤ 0.05. All data are presented as mean ± SEM.
3. Results
3.1. Age-dependent pro-inflammatory cytokine expression in 5xFAD mice
The 5xFAD (Tg) mouse model of Alzheimer’s disease displays progressive amyloid beta 
plaque accumulation before 3 months of age, progressive synaptic protein loss as well as 
later neuronal degeneration, and cognitive deficits by 5 months of age (Oakley et al., 2006). 
In this model we found age-dependent and region-specific increases in inflammatory 
mRNAs within the CNS but minimal evidence of inflammation in the CSF, as measured by 
multiplexed immunoassay. Tg mice, male and female, were not found to express 
significantly different levels of several cytokines in CSF at 2, 4, or 6 months of age. Levels 
of mKC/CXCL1 protein are significantly lower in Tg mice at 6 months of age (non-Tg mean 
7.962 ± 0.438 pg/mL; Tg mean 4.3033 ± 1.481 pg/mL df = 5 t = 2.724 p < 0.05 *, Table 1A; 
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CSF levels of INFγ, IL-10, IL-1β, IL-6 and IL-12 p70 protein levels undetectable). TNF 
protein levels are not detectable at 2 month of age and no significant differences were found 
at 4 and 6 months of age. Within the cortex, there was a significant increase in expression of 
CD45 mRNA at 6 months Tg mice as compared to non-Tg mice, male and female, (non-Tg 
mean = 1.188 ± 0.138 fold change, Tg mean = 2.901 ± 0.415 fold change from 2 month non-
Tg baseline by 2-way ANOVA df = 58 t = 7.107 p < 0.0001, Table 1B). Within the midbrain, 
expression of CD45 and TNF mRNA was significantly increased at 6 months in Tg mice as 
compared to non-Tg mice (TNF: non-Tg = 1.21 ± 0.147, Tg = 3.325 ± 0.731 fold change 
from 2 month non-Tg baseline by 2-way ANOVA df = 57, t = 5.560, p < 0.05; CD45: non-
Tg = 1.122 ± 0.074, Tg = 3.276 ± 0.586 fold change from 2 month non-Tg baseline by 2-
way ANOVA df = 58 t = 7.895 p < 0.0001, Table 1B).
3.2. Altered peripheral immune cell populations in the pro-inflammatory Tg CNS 
environment
Immune cells were isolated from the CNS of Tg and non-Tg mice at 3.5, 5, 7, and 12 
months of age. These ages correspond to early stages of amyloid deposition (3.5 months), 
onset of cognitive impairment (5 months), and aggressive amyloid burden (7 and 12 months) 
(Oakley et al., 2006). Here, we show that populations of immune cells trafficking into the 
brain were altered between Tg and non-Tg mice as a function of age. Peripheral 
macrophages that have trafficked into the brain are CD11b+ and CD45high. 
CD45highCD11b+ cells historically have been identified solely as peripheral macrophages 
however microglia, while they are in majority CD45low, have been shown to be capable of 
expression CD45 at high levels when activated (Sedgwick et al., 1991). Thus our 
CD45highCD11b+ population was not purely peripheral macrophages but also contained 
activated microglia and dendritic cells, which also express CD11b and CD45 at high level; 
neutrophils were gated out of this population using the marker Ly6G (Rose et al., 2012). 
Within the brain, there was no effect of genotype or age on the number of CD11b+CD45high 
cells (data not shown), however within this population there was a significant decrease in the 
frequency of CD11b+ - CD45highMHCII+ cells in Tg mice as compared to non-Tg at 7 
months of age, (non-Tg = 4.240 ± 0.213%, Tg = 2.601 ± 0.316% by 2-way ANOVA df = 53 
t = 5.061 p < 0.0001, Fig. 1B). MHCII is used by antigen presenting cells, such as 
macrophage and microglia of the innate immune system, activate CD4+ T cells of the 
adaptive immune system (Neefjes et al., 2011). In Tg mice, there was a significant increase 
in the ratio of CD11b+ Ly6Chigh:Ly6Clow at 5 months in the brain as compared to non-Tg 
mice, (non-Tg = 0.098 ± 0.004, Tg = 0.171 ± 0.018 by 2-way ANOVA df = 38 t = 2.722 p < 
0.05, Fig. 1B).
Immune cells, including T cells, neutrophils, and dendritic cells, will traffic to tissues 
including the brain to conduct immune surveillance and respond to inflammation (Ransohoff 
and Brown, 2012; Ransohoff and Engelhardt, 2012). In the brain of Tg and non-Tg mice, 
there were no significant differences in the frequency or number of neutrophils (CD3− 
Ly6G+), B cells (CD3− Ly6G−CD11b−CD19+), or dendritic cells 
(CD3−Ly6G−CD11b+CD11c+), (data not shown). At 12 months of age, the frequency of 
CD3+ T cells of all CD45+ brain cells was significantly increased in Tg mice as compared to 
non-Tg mice (non-Tg = 20.822 ± 2.919% Tg = 34.000 ± 3.506% by 2-way ANOVA df = 72 
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t = 3.636 p < 0.01, Fig. 1C). Within this population, CD4+ and CD8+ T cells were measured 
(Fig. 1C). The number of CD4+ T cells was not significantly different between Tg and non-
Tg mice, however, at 12 months of age, there was a significant increase in the number of 
CD8+ T cells in the brains of Tg mice as compared to non-Tg mice (non-Tg = 5622.937 
± 1238.101 Tg = 13.098.990 ± 2637.522 by 2- way ANOVA df = 67 t = 3.903 p < 0.001, 
Fig. 1D). Within the CD8+ T cell population, naïve, effector, and memory subtypes were 
assessed via expression of CD62L and CD44 expression level. Tg mice show alterations of 
the CD8+ effector (CD62L− CD44−) T cell population as compared to non-Tg. At 3.5 
months of age, there was a significant decrease in the frequency of CD8+ effectors (non-Tg 
= 73.125 ± 3.744% Tg = 42.978 ± 14.773% by 2-way ANOVA df = 37 t = 2.692 p < 0.05, 
Fig. 1E), and at 5 months of age, there was a significant increase in the number of CD8+ 
effectors (non-Tg = 3166.673 ± 661.671 Tg = 5604.624 ± 902.898 by 2-way ANOVA df = 
36 t = 2.979 p < 0.05, Fig. 1E). No significant changes were detected in the other 
subpopulations of CD8+ or CD4+ T cells (data not shown).
3.3. Altered naïve and effector T cell populations in deep cervical lymph nodes of Tg mice
No significant differences in the number of CD4+ or CD8+ T cells were found in the DCLNs 
or spleen between Tg and non-Tg mice (data not shown). However, within the CD4+ and 
CD8+ T cell populations in the DCLN, but not spleen (data not shown), Tg mice showed 
increased frequency of CD4+ and CD8+ naïve (CD62L+CD44low) T cells, and decreased 
frequency of effector T cells, at 5 months (CD4+ naïve non-Tg = 55.825 ± 5.198% Tg = 
75.425 ± 3.123% by 2-way ANOVA df = 29 t = 2.927 p < 0.05, CD4+ effector non-Tg = 
36.375 ± 5.344% Tg = 15.450 ± 1.023% by 2-way ANOVA df = 28 t = 3.796 p < 0.01, Fig. 
2A; CD8+ naïve non-Tg = 51.000 ± 3.143% Tg = 70.025 ± 2.885% by 2-way ANOVA df = 
29 t = 3.123 p < 0.05, CD8+ effector non-Tg = 38.650 ± 3.847% Tg = 22.075 ± 2.893% by 
2-way ANOVA df = 28 t = 2.841 p < 0.05, Fig. 2B). In the DCLN, CD4+ and CD8+ T cell 
subsets shifted with age towards memory phenotypes. Frequency of both central and effector 
memory CD4+ T cells subsets was significantly increased at 12 months in both genotypes 
from all other time points in both spleen and DCLNs (data not shown). Frequency of central 
memory CD8+ T cells was significantly increased at 12 months in both genotypes from all 
other time points in both spleen and DCLNs (data not shown). Frequency of effector 
memory CD8+ T cells was significantly decreased in the DCLNs in Tg mice as compared to 
non-Tg mice at 12 months of age, (non-Tg = 7.598 ± 0.518% Tg = 4.473 ± 1.197% by 2-
way ANOVA df = 29 t = 3.111 p < 0.05 (data not shown)).
3.4. Inhibition of soluble TNF decreases brain populations of activated CD11b+ immune 
cells and CD4+ T cells
Tg mice were treated with s.c. XPro1595 (10 mg/kg) twice weekly for two months starting 
at 5 months of age or starting at 2 months of age to assess the role of sTNF on AD-like 
pathology after significant plaque deposition or as plaque deposition begins to build up, 
respectively. Inhibition of soluble TNF with XPro1595 between 5 and 7 months of age 
decreased MHCII+ microglia/macrophages within both populations of activated microglia/
peripheral cells (CD11b+CD45high;frequency but not number) and quiescent/homeostatic 
resident microglia (CD11b+CD45low; frequency and number) immune cells (activated/
peripheral MHCII+: frequency - non-Tg = 5.811 ± 0.5256% Tg = 3.843 ± 0.2614% by 
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unpaired t-test df = 16 t = 3.352 p < 0.01, number - non-Tg = 1676 ± 186.7 Tg = 1334 
± 174.7 by unpaired t-test df = 16 t = 1.331 p = 0.2020; quiescent/homeostatic 
MHCII+:frequency - non-Tg = 4.440 ± 0.4430% Tg = 2.678 ± 0.3250% by unpaired t-test df 
= 17 t = 3.252 p < 0.01, number - non-Tg = 1309 ± 233.0 Tg = 744.2 ± 113.6 by unpaired t-
test df = 15 t = 2.260 p < 0.05, Fig. 3A). While these effects on MHCII+ populations were 
not observed in Tg mice dosed between 2 and 4 months of age, there was an overall decrease 
in the frequency of CD11b+ CD45high populations and an increase in CD11b+CD45low 
populations (CD45high - non-Tg = 15.44 ± 1.633% Tg = 10.53 ± 1.14%2 by unpaired t-test 
df = 12 t = 2.293 p < 0.05; CD45low - non-Tg = 84.51 ± 1.639% Tg = 89.43 ± 1.147% by 
unpaired t-test df = 12 t = 2.290 p < 0.05, Fig. 3F).
Xpro1595 from 5 to 7 months in Tg mice decreased the ratio of Ly6Chigh:Ly6Clow CD11b+ 
immune cells however the individual cell counts of Ly6Chigh and Ly6Clow populations were 
not significantly different with XPro1595 treatment (Ly6Chigh:Ly6Clow - non-Tg = 0.2133 
± 0.02147 Tg = 0.1335 ± 0.02178 by unpaired t-test df = 14 t = 2.571 p < 0.05; Ly6Chigh 
count - non-Tg = 822.1 ± 163.3 Tg = 630.5 ± 125.5 by unpaired t-test df = 14 t = 0.8855, p = 
n.s., Ly6Clow count - non-Tg = 4084 ± 741.1 Tg = 5921 ± 1625 by unpaired t-test df = 14 t = 
1.112 p = n.s., Fig. 3B). When mice were dosed between 2 and 4 months of age, there was a 
trend for a decreased ratio of Ly6Chigh:Ly6Clow of CD11b+ immune cells in Tg mice 
(Ly6Chigh:Ly6Clow - non-Tg = 0.1225 ± 0.01449 Tg = 0.08311 ± 0.01334 by unpaired t-test 
df = 12 t = 1.933 p = 0.0772, Fig. 3G).
Among the other immune cell populations in the brain, no changes were detected in 
frequency or number of B cells or neutrophils when XPro1595 was dosed from 5 to 7 
months of age in Tg mice (data not shown). Within the dendritic cell population, there was a 
significant increase in frequency of CD11c+ cell population in the brain (CD11b+–CD11c+ 
Frequency - non-Tg = 10.12 ± 0.8053% Tg = 16.78 ± 12.116% by unpaired t-test df = 14 t = 
3.229 p < 0.001); however there was no significant increase in cell number (data not shown). 
When mice were dosed with XPro1595 between 2 and 4 months of age, there was no 
significant increase in the number or frequency of CD11c+ cells within the CD11b+ 
population (data not shown). Within this population, only when XPro1595 was dosed 
between 2 and 4 month of age but not when dosed between 5 and 7 months of age, there was 
a significant decrease in the frequency of a MHCII+ populations 
(CD11b+CD11c+MHCII+ 2–4 months XPro1595: non-Tg = 5.775 ± 0.7116% Tg = 3.113 
± 0.2031% by unpaired t-test df = 12 t = 3.138 p < 0.01).
In Tg mice treated with XPro1595 from 5 to 7 months, CD3+ T cell populations were 
decreased by XPro1595 treatment in frequency but not in number (CD3+ Frequency - non-
Tg = 24.64 ± 1.817% Tg = 18.88 ± 1.349% by unpaired t-test df = 16 t = 2.548 p < 0.05, 
Count - non-Tg = 14.427 ± 1390 Tg = 11.963 ± 1829 by unpaired t-test df = 17 t = 1.054 p = 
n.s., Fig. 3C). Within the T cell population, inhibition of sTNF did not induce any significant 
changes within the CD8+ T cell population (CD8+ T cell count non-Tg = 9333 ± 2233 Tg = 
6811 ± 1572 by unpaired t-test df = 11 t = 0.9509 p = n.s.; CD8+ Effector T cell count non-
Tg = 7536 ± 1876 Tg = 4234 ± 786.1 by unpaired t-test df = 8 t = 1.623 p = n.s. Fig. 3E); 
however, there was a significant decrease in the number of CD4+ T cells and a trend for 
decreased number of CD4+ effector T cells in Tg mice treated with XPro1595 between 5 and 
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7 months of age (CD4+ T cell count - non-Tg = 4244 ± 725.7 Tg = 2369 ± 305.9 by 
unpaired t-test df= 11 t = 2.746 p < 0.05, CD4+ effector T cell count - non-Tg = 4151 
± 734.9 Tg = 2263 ± 427.5 by unpaired t-test df = 8 t = 2.221 p = 0.0571, Fig. 3D). 
Inhibition of sTNF from 2 to 4 months did not produce any significant effects in T cells 
populations in Tg mice (CD8+ T cell count - non-Tg = 3010 ± 508.8 Tg = 7872 ± 3025 by 
unpaired t-test df = 12 t = 1.834 p = n.s., CD4+ T cell count - non-Tg = 1886 ± 308.9 Tg = 
2701 ± 238.7 by unpaired t-test df = 11 t = 1.862 p = n.s., Fig. 3H.)
3.5. Inhibition of soluble TNF increases the naive T cell populations in the DCLNs of Tg 
mice
In mice treated with XPro1595 between 5 and 7 months of age in Tg mice, no significant 
changes were seen in the number of total CD8+ or CD4+ T cells in DCLN (CD4+ T cell 
count - non-Tg = 43.112 ± 8847 Tg = 100.768 ± 29,891 by unpaired t-test df = 16 t = 1.670 
p = n.s. Fig. 4A; CD8+ T cell count - non-Tg = 43,901 ± 10,246 Tg = 71.747 ± 17,832 by 
unpaired t-test df = 15 t = 1.308 p = n.s., Fig. 4D); however, within the CD4+ and CD8+ 
populations, there were significant changes in the effector and naïve populations. Within the 
CD4+ T cells, there was a trend for an increase in the frequency and a significant increase in 
the number of naïve T cells in in XPro1595-treated Tg mice (CD4+ naïve frequency - non-
Tg = 46.01 ± 5.005% Tg = 61.00 ± 5.962% by unpaired t-test df = 13 t = 1.940p = n.s.; 
CD4+ naïve count - non-Tg = 18.548 ± 4598 Tg = 73.129 ± 23,124 by unpaired t-test df = 
13 t = 2.473 p < 0.05, Fig. 4B); however, no significant changes were found in the CD4+ 
effector T cells (CD4+ effector Frequency - non-Tg = 42.36 ± 5.331% Tg = 27.46 ± 6.335% 
by unpaired t-test df = 13 t = 1.814 p = n.s.; CD4+ effector count - non-Tg = 17.979 ± 4168 
Tg = 24.819 ± 10,240 by unpaired t-test df = 16 t = 0.5654 p = n.s., Fig. 4C). Within the 
CD8+ T cells, there was a significant increase in the frequency and number of naïve T cells 
(CD8+ naïve frequency - non-Tg = 46.35 ± 5.793% Tg = 65.76 ± 6.619% by unpaired t-test 
df = 13 t = 2.217 p < 0.05; CD8+ naïve count - non-Tg = 19.948 ± 5588 Tg = 80.549 
± 28,025 by unpaired t-test df = 13 t = 2.265 p < 0.05, Fig. 4E) and a significant decrease in 
the frequency, but not number, of effector T cells (CD8+ effector frequency - non-Tg = 42.73 
± 5.339% Tg = 22.07 ± 5.048% by unpaired t-test df = 13 t = 2.787 p < 0.05; CD8+ effector 
count - non-Tg = 18.953 ± 5212 Tg = 14.172 ± 4231 by unpaired t-test df = 12 t = 0.6760 p 
= n.s., Fig. 4F).
When dosed from 2 to 4 months of age, Tg mice showed an increase in the frequency, but 
not number, of CD8+ T cells and decrease in the frequency, but not number, of CD4+ T cells 
(CD8+ frequency - non-Tg = 36.88 ± 3.110% Tg = 44.69 ± 1.444% by unpaired t-test df = 
13 t = 2.169 p < 0.05; CD4+ frequency - non-Tg = 54.91 ± 2.134% Tg = 47.60 ± 1.588% by 
unpaired t-test df = 13 t = 2.681 p < 0.05). Within the CD4+ T cell population there were no 
changes in measured subpopulations, however there was a trend for increased frequency of 
CD8+ central memory T cells (CD8+ central memory frequency - non-Tg = 4.326 
± 0.3614% Tg = 6.817 ± 1.296% by unpaired t-test df = 13 t = 1.966 p < 0.05).
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3.6. Inhibition of soluble TNF decreases amyloid β and cytokine expression in the 
hippocampus of Tg mice
Inhibition of sTNF significantly decreased the density (% of area) of amyloid-β in the 
subiculum, but not the entire hippocampus, of Tg mice (Subiculum - Tg Saline = 57.92 
± 1.736% Tg XPro1595 = 51.49 ± 0.9899% by unpaired t-test df = 6 t = 3.216 p < 0.05; 
Hippocampus - Tg Saline = 27.67 ± 1.556%TgXPro1595 = 26.51 ± 1.543% by unpaired t-
test df = 6 t = 0.5296 p = n.s., Fig. 5A). Specifically, within the subiculum, there was a 
significant decrease in amyloid-β density in the dorsal and posterior subiculum (when the 
dorsal and ventral subiculum come together anatomically) but not the ventral subiculum 
(Dorsal Subiculum - Tg Saline = 69.83 ± 2.197% Tg XPro1595 = 63.32 ± 1.438% by 
unpaired t-test df = 6 t = 2.481 p < 0.05., Fig. 5A; Ventral Subiculum - Tg Saline = 37.76 
± 1.730% Tg XPro1595 = 32.16 ± 2.951% by unpaired t-test df = 6 t = 1.897 p = n.s., Fig. 
5A; Posterior Subiculum - Tg Saline = 56.10 ± 2.159% Tg Xpro1595 = 47.93 ± 1.178% by 
unpaired t-test df = 6 t = 3.322 p < 0.05, data not shown). No significant changes were seen 
in the hippocampus or subiculum in the density of amino cupric silver stain which denotes 
disintegration of multiple neuronal elements including cell bodies, axons, dendrites, and 
synaptic terminals (Hippocampus - Tg Saline = 34.52 ± 1.348% Tg XPro1595 = 31.68 
± 2.370% by unpaired t-test df = 6 t = 1.037 p = n.s., Fig. 5B; Subiculum - Tg Saline = 
60.96 ± 1.873% Tg XPro1595 = 57.18 ± 1.816% by unpaired t-test df = 6 t = 1.450 p = n.s., 
Fig. 5B; Dorsal Subiculum - Tg Saline = 66.11 ± 1.694% Tg XPro1595 = 62.45 ± 1.734% 
by unpaired t-test df = 6 t = 1.509 p = n.s., Fig. 5B; Ventral Subiculum - Tg Saline = 52.72 
± 3.214% Tg XPro1595 = 46.87 ± 3.022% by unpaired t-test df = 6 t = 1.325 p = n.s., Fig. 
5B; Posterior Subiculum - Tg Saline = 61.49 ± 1.689% Tg XPro1595 = 57.50 ± 1.381% by 
unpaired t-test df = 6 t = 1.831 p = n.s., data not shown).
When the contralateral hemisphere was used to measure transcriptional changes in gene 
expression, gene expression associated with an inflammatory response and its resolution was 
found to be reduced by inhibition of sTNF with XPro1595. TGFβ and CCL2 mRNA 
expression was significantly reduced in Tg mice, but not non-Tg mice, treated with 
XPro1595 from between 5 and 7 months of age. (CCL2 Tg saline = 6.713 ± 1.170 Tg 
XPro1595 = 4.055 ± 0.953 by 2-way ANOVA df = 18 t = 2.858 p < 0.05; TGFβ Tg saline = 
3.255 ± 0.257 Tg XPro1595 = 2.547 ± 0.201 by 2-way ANOVA df = 18 t = 4.624 p < 0.01, 
Table 2, Fig. 5C).
3.7. XPro1595 blocked LTP deficits in 5xFAD mice
Deficits in hippocampal CA1 synaptic function have been reported in several mouse models 
of AD and are associated with cognitive deficits. To determine if in vivo peripheral 
administration of XPro1595 modulates synaptic function in Tg mice, brain slices were 
harvested for analysis of CA3-CA1 synaptic strength curves (Fig. 6A–B) and LTP levels 
(Fig. 6F–H). At four months of age, basal synaptic strength deficits were found to be 
relatively mild in vehicle-treated Tg mice, characterized by a modest downward shift in the 
synaptic strength curve and a significant reduction (p < 0.05) in the maximal EPSP/FV ratio, 
relative to non-Tg vehicle-treated mice (Fig. 6C). XPro1595 had minimal effect on synaptic 
strength (Fig. 6A–B), though it did slightly reduce and slightly increase the maximal 
EPSP/FV ratio in non-Tg and Tg mice, respectively (Fig. 6C). No genotype or XPro1595 
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treatment effects were observed for PPF measures or population spike threshold (Fig. 6D–
E). LTP was induced in area CA1 using two 100 Hz-stimulus trains (one second duration) 
separated by 10 s. Consistent with PPF measures, post-tetanic EPSP values during the 5–10 
min period after 100 Hz stimulation was similar across genotypes, indicating the absence of 
pre-synaptic deficits in 5xFAD mice at this age. However, relative to vehicle-treated non-Tg 
mice, the Tg group showed a significant reduction in LTP levels at 60 min post-100 Hz 
stimulation (153.3 ± 9.5% vs 125.3 ± 5.7%, p < 0.05) that was blocked by in vivo treatment 
with XPro1595 (158.2 ± 5.1%, p < 0.05 vs Tg vehicle group) (Fig. 6G). In contrast, 
XPro1595 had minimal effect on LTP in non-Tg mice (141.4 ± 15.7%, Fig. 6H). Together, 
these results demonstrate that XPro1595 protects against age-dependent LTP deficits in Tg 
mice and does not disrupt LTP mechanisms in non-Tg mice.
4. Discussion
Chronic inflammation induced by metabolic syndrome and obesity is associated with 
increased risk for AD and may accelerate disease progression. While chronic anti-
inflammatory usage has been associated epidemiologically with lower incidence of AD, 
global targeting of inflammatory pathways in clinical trials has had limited success in 
slowing cognitive decline, either because the targets are wrong or the intervention too late 
(McGeer and McGeer, 2007) Yet, global immuno-suppression is not likely to be a viable 
therapeutic strategy to treat neuroinflammation in AD. Our data support specific targeting of 
sTNF/TNFR1 signaling in regulating alterations in immune cell populations associated with 
AD-like synaptic deficits (Fig. 7). Specifically, Tg mice develop an age-dependent pro-
inflammatory environment within the brain without evidence of robust CSF or peripheral 
inflammation; therefore, alterations observed in peripheral immune cells are in response 
solely to changes in brain inflammation and not additional peripheral inflammatory signals. 
Immune cells in Tg mouse brain display changes suggestive of altered communication 
between the innate and adaptive immune system arms. These observed changes appear at 
different ages suggesting these trafficking populations may play specific roles at specific 
points during the progression of the AD-like phenotype. As evidenced by a significant 
decrease in TGFβ and CCL2 mRNA in hippocampus, this inflammation is partially 
mitigated by inhibition of sTNF (Table 2). Decreased CCL2 mRNA suggests that 
recruitment of peripheral immune cells is dampened with inhibition of sTNF. Decreased 
TFGb mRNA suggests TGFb-dependent regulation of inflammation is no longer occurring 
with sTNF inhibition. This selective response may be attributed to multiple inflammatory 
pathways also regulating expression of multiple inflammatory factors. Moreover, Aβ load in 
the subiculum and hippocampal LTP impairment are mitigated with in vivo treatment of 
XPro1595 in association with changes in brain and draining DCLNs.
The increase in cytokines in response to ongoing AD-like pathology at 6 and 7 months 
suggests that peripheral immune cells may be actively recruited to the pro-inflammatory 
environment of the brain in Tg mice, implicating the peripheral immune system in 
modulating progression of AD-like pathology. In support of this, studies have shown that the 
trafficking of peripheral macrophages to the CNS is necessary for mitigating plaque burden 
(El Khoury et al., 2007). However, a recent study reported that recruitment of peripheral 
macrophages is not sufficient to clear accumulated plaque (Varvel et al., 2015). Taken 
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together, these data suggest the CNS resident microglia must be working in concert with 
peripheral immune cells to combat the accumulation of aggregated Aβ and in modulating 
synaptic function.
Our findings revealed alteration in CNS recruitment and activation status of peripheral 
immune cells either before or after they enter the brain parenchyma. Within the myeloid 
compartment of the innate immune system, overall changes in the frequency of 
CD45highCD11b+ cells, a population that contains peripheral immune cells as well as 
activated microglia, was not increased in Tg mice with age. Here we surveyed total brain 
populations thus suggesting that while globally there are not changes in the 
CD45highCD11b+ cell population that there may be regional changes that associated with 
increased pathology or response to experimental treatments. Inhibition of sTNF increased 
the frequency of CD11b+CD11c+ population in Tg mice. CD11c is used as a marker of 
dendritic cells, however a population of CD11b+ CD11c+ cells within the brain parenchyma 
have been shown to display a microglial, rather than dendric cell, phenotype based on 
surface marker expression as well as morphology (Dando et al., 2016). This population has 
been shown to expand in response to neuroinflammation and while increasing levels of 
MHCII equivalent to blood derived CD11c+ cells, express a different cytokine profile 
(Wlodarczyk et al., 2014). CD11c+ microglia that accumulate around amyloid plaques show 
increased anti-inflammatory genomic expression as compared to CD11c− microglia 
(Kamphuis et al., 2016). The increase in CD11b+CD11c+ cells could thus be interpreted as 
an increased in CD11c+ microglia that preform a specific anti-inflammatory function within 
the inflamed brain. Our data revealed changes in activation status of recruited cells, high 
expression of Ly6C correlates with expression of CCR2 and higher capacity for 
phagocytosis while Ly6Clow expression correlates with expression of CX3CR1 and anti-
inflammatory actions (Yang et al., 2014). The ratio of Ly6C expression can reveal shifts in 
the activation status of macrophage populations towards pro-inflammatory, phagocytic 
activation (higher ratio) or towards alternative anti-inflammatory activation (lower ratio). 
Our data indicated the ratio of CD11b+Ly6Chigh to Ly6Clow had shifted in Tg mice towards 
more Ly6Chigh cells. These changes in Ly6C suggest that the Ly6C+CD11b+ myeloid cells 
in the CNS of Tg mice, potentially infiltrating macrophages, may be more active than the 
infiltrating macrophages in non-Tg CNS. This may be an adaptive response to combat 
plaque accumulation, however peripheral macrophages from AD patients are less phagocytic 
as compared to healthy controls (Fiala et al., 2005), suggesting the phagocytic capabilities of 
these cells may be impeded.
A recent study reported in 5xFADxRAG mice lacking functional T cells, B cells, and some 
NK cells significantly increased amyloid β load, indicating that the adaptive immune system 
plays a key role in mitigating AD-like pathology (Marsh et al., 2016). In agreement with 
others (Bryson and Lynch, 2015), we found increased numbers of T cells in the brains of Tg 
mice at later stages. Specifically, we found increased CD8+ T cells but not CD4+ T cells. 
The frequency of CD8+ effector T cells is decreased in Tg mice at 3.5 months, without a 
change in number of CD8+ effector T cells, suggesting subtle changes in CD8+ naïve and 
memory subsets has decreased the proportion of CD8+ T cells that are effectors. At the 
following time point the decrease in CD8+ effector T cells is no long seen in Tg mice, due to 
a significant increase in the number of CD8+ effector T cells. This response maybe an 
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adaptive response to the change in frequency seen at the earlier time-point to return the 
frequency distribution of CD8+ T cell subsets to a homeostatic level seen in non-Tg mice. 
Cytotoxic CD8+ T cells are increased in the AD brain and likely have negative consequences 
for neuronal function and integrity (Togo et al., 2002). While CD8+ effector cells were not 
decreased in the brain with sTNF inhibition (potentially because the dosed time point is 
earlier than when we see significant differences in CD8+ T cells), the CD3+ T cell 
population was decreased due to a significantly decreased CD4+ T cell subpopulation and is 
likely to be due to a trend in decreased CD4+ effector cells. Effector CD4+ T cells functions 
range from prionflammatory to regulatory, which may have very different consequences on 
AD-like pathology, specific regulation of T cell subsets has therapeutic potential yet the role 
of these subsets in AD needs further investigation.
Our findings also shed light on the potential role for antigen presentation in progression of 
AD-like pathology. Major histocompatibility complex II (MHCII) is used by antigen 
presenting cells (APCs), such as microglia and macrophage, to activate CD4+ T cells in an 
antigen specific manner. MHCII is important for crosstalk between the innate and adaptive 
immune systems and for presentation of antigens to activate CD4+ T cells (Neefjes et al., 
2011). Decreases in MHCII frequency may suggest that cross talk between APCs and T cells 
is diminished and CD4+ T cell activation is decreased. We show that Tg mice have decreased 
frequency of CD11b+CD45highMHCII+ brain immune cells. This is contrary to reports of 
increased MHCII reactivity around plaques in the human AD brain (Perlmutter et al., 1992). 
It is important to note, however, that animal models do not fully recapitulate human disease 
and in particular, our data were not derived from the most advanced stages of AD-like 
pathology in Tg mice levels of MHCII+ cells in the brain measured by flow cytometry 
reflect the net levels in the brain and region-specific differences certainly exist which can 
only be accurately captured using immunohistological approaches. Specifically, it is possible 
that MHCII+ cells are enriched around amyloid plaques while across the brain there may be 
overall decreases in the total CD11b+ - CD45highMHCII+ population. Importantly, across all 
CD11b+ cells, there were no effects of genotype on MHCII expression only within this 
particular subset of CD45high cells that contains peripheral macro-phages as well as 
activated microglia. Therefore, the decreased MHCII observed in Tg mice suggests that 
communication and subsequent activation of brain CD4+ T cells by infiltrating 
macrophages/activated microglia (CD11b+CD45high) is impaired; this may or may not be an 
adaptive response. CD4+ T cells can have both pro-inflammatory and protective regulatory 
effects (Wan and Flavell, 2009). In our study, we found that primarily effector CD4+ T cells 
in the brain, which can be pro-inflammatory or regulatory, were decreased following 
XPro1595. One subset of CD4+ effector T cells, CD4+ regulator T cells (Treg), suppressors 
of immune responses, have been shown to be elevated in elderly populations, and shown to 
have increased suppressive activity in AD patients (Rosenkranz et al., 2007). In an AD 
mouse model removal of Treg suppressive effect on the immune system, via transient 
depletion or inhibition, increased leukocyte trafficking at the choroid plexus, increased brain 
CD45highCD11b+ and Treg populations, as well as decreased plaque burden, pro-
inflammatory cytokine mRNA expression, and improved on cognitive function (Baruch et 
al., 2015). Further investigation may reveal changes within effector CD4+ T cells, 
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specifically Tregs, in the brain and will enhance our understanding of how changes in 
MHCII contribute to or protect against AD-like pathology.
T cells residing in the DCLNs have the opportunity to encounter antigens and other soluble 
factors draining from the brain. Our data revealed that Tg mice have populations of CD4+ 
and CD8+ T cells skewed towards significantly more naïve cells and fewer effector cells 
within the DCLNs. These T cells may then become primed to carry out their functions in the 
brain. While there were no significant differences in the overall number of T cells, fewer of 
these were effector cells in the DCLNs of Tg mice, suggesting they may be elsewhere (i.e. in 
the blood on route to the brain) or alternatively, that there is impaired crosstalk between the 
innate and adaptive immune system in Tg mice. The increased population of CD8+ effector 
cells that we see in the brain of Tg mice suggests the former; that these cells are trafficking 
from the DCLN where they may have first been exposed to brain antigen and have now 
moved into the brain where they will perform their effector functions. In Tg mice the 
frequency of CD4+ and CD8+ effector T cells is decreased in the DCLNs, without 
corresponding changes in number of T cell subsets, these results may suggest that the 
localization of these T cells is altered by plaque pathology. The CD8+ effector T cell 
population is increased in the brain at 5 months of age suggesting that there may be 
increased trafficking from the DCLNs to the brain in Tg mice. Future studies will explore 
the soluble factors (including amyloid β) within the DCLNs that may be activating these T 
cells. With inhibition of sTNF, we observe an increased number of naïve CD4+ and CD8+ T 
cells within the DCLN. Despite the fact that we observe no change in the number of effector 
T cells within the DCLNs following sTNF inhibition, the cells within this population may be 
changed in function, given that sTNF can act as a regulator of effector T cell activation 
(Evangelidou et al., 2010). This and other possibilities will be explored in future studies that 
assess the profile of secreted cytokines along with histological markers of tissue 
inflammation.
The changes we observed in T cell profiles in the DCLNs and in immune cell profiles in the 
brain following XPro1595 are most likely due to direct inactivation of sTNF/TNFR1 
signaling on immune cells. sTNF is an inflammatory mediator of BBB permeability 
activating cells along brain capillaries, leading to up-regulation of factors that facilitate 
immune cell entry across the BBB (Nadeau and Rivest, 1999; Rezai-Zadeh et al., 2009). 
Regulation of downstream factors of sTNF/TNFR1 signaling, such as Lipocalin 2 (Lcn2), 
may also be contributing to effects seen by XPro1595. Lcn2 expression is significantly 
increased in the AD brain, has been shown to impair neuroprotective TNFR2 signaling, and 
increase Aβ toxicity (Naude et al., 2012). As a measurement of pathology outcome we also 
measured amyloid plaque via IHC. We found a small, yet significant decrease in amyloid 
(6E10) density indicating that sTNF may play a role in the production or accumulation of 
amyloid pathology. Further investigation of the roll of soluble TNF inhibition on the 
mechanisms of plaque accumulation may be warranted based upon this data.
Finally, the most promising finding in our study is the ability of XPro1595 to restore LTP in 
Tg mice because it is clear that synaptic dysfunction is responsible for memory deficits and 
cognitive decline in AD. Future studies will be aimed at determining the extent to which the 
restoration of LTP resulting from sTNF signaling inhibition was due to decreased amyloid 
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deposition in the hippocampus or via direct effect on synaptic physiology. However, given 
that TNF can inhibit LTP (Cunningham et al., 1996) and that sTNF promotes long-term 
depression (LTD) in aged rats (Sama et al., 2012), our findings with XPro1595 in 5xFAD 
mice strongly suggest that sTNF is likely to be directly mediating the LTP deficits in Tg 
mice. sTNF has been shown to play an important role in potentiating glutamate 
excitotoxicity, through direction activation of NMDA receptors and increasing AMPA 
receptor localization at the synapse, while transmembrane TNF/TNFR2 signaling has been 
implicated in protection against excitotoxicity (McCoy and Tansey, 2008). Inhibition of 
sTNF via XPro1595 may be modulating these direct mechanisms of sTNF at the synapse as 
well as modulating BBB permeability and immune cell activation. Further investigation may 
reveal that modulating these multiple mechanisms of sTNF may be contributing to the 
overall effects on LTP and immune cell trafficking. Our group has shown that peripherally 
administered XPro1595 gets across the BBB and is able to sequester the picomolar levels of 
sTNF within the brain (Barnum et al., 2014); however, a recent clinical study with a non-
BBB crossing TNF inhibitor (etanercept), implicates a TNF-dependent peripheral 
mechanisms in the cognitive decline associated with AD pathogenesis (Butchart et al., 
2015). Together, these data suggest that TNF can have both direct effects on synaptic 
physiology as well as indirect effects on peripheral cytokines and immune cell traffic to the 
CNS and brain resident immune cells and thus, targeting sTNF centrally and peripherally 
may afford added advantage to improve functional outcomes in patients with AD.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. 
Altered peripheral immune cell populations in the pro-inflammatory AD-like brain 
environment. A) Graphical depiction of select results from Table 2. At 7 months of age 
CCL2 and TNF mRNA expression is significantly increased in the hippocampus of Tg mice 
as compared to non-Tg mice. By flow cytometry, populations of immune cells within the 
brain were measured at 3.5, 5, 7, and 12 months of age in non-Tg and Tg mice. B) While 
there are no effects of genotype on frequency or number of CD11b+ (microglia and 
macrophage) or CD11b+CD45high (peripheral macrophage and activated microglia) immune 
cells (data not shown), there is a significant decrease in the frequency of 
MHCII+CD45highCD11b+ cells in the brain of Tg mice compared to that in non-Tg mice at 7 
months of age, ****p < 0.0001. At 5 months of age the ratio of Ly6Chigh:Ly6Clow is 
significantly increased as compared to non-Tg mice * p < 0.05. C) At 12 months of age the 
frequency of CD3+ T cells in significantly increased in Tg mice as compared to non-Tg 
mice, ** p < 0.01. Contour plot inset shows CD4 and CD8 gating on the brain CD3+ T cell 
population. Within this population, subsets of CD4+ and CD8+ T cells were measured. D) In 
both non-Tg and Tg mice, the number of CD4+ T cells increases within the CNS with age. 
No effects were seen within the CD4+ T cell population. In Tg mice there was a significant 
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increase in the number of CD8+ T cells within the CNS at 12 months of age, ***p < 0.001. 
E) Within the CD8+ T cell population, there is a significant decrease in the frequency of 
CD8+ effector T cell (CD62L−CD44−) population in Tg mice as compared to non-Tg mice 
at 3.5 months of age. By 5 months of age, the frequency of CD8+ effector cells has increased 
in Tg mice to non-Tg levels. At this same time point, there is a significant increase in the 
number of CD8+ effector T cells within the brain that can account for this return to non-Tg 
frequency levels, * p < 0.05.3.5 months: non-Tg n = 8, Tg n = 9; 5 months: non-Tg n = 11, 
Tg n = 11;7 months: non-Tg n = 11, Tg n = 13;12 months: non-Tg n = 10, Tg n = 9. Within 
these groups, subsets with robust MHCII and Ly6C staining were used for analysis of these 
markers in the brain: 3.5 months: non-Tg n = 8 (MHCII)/5 (Ly6C), Tg n = 9/4; 5 months: 
non-Tg n = 4/7, Tg n = 7/8; 7 months: non-Tg n = 8/6, Tg n = 11/7; 12 months: non-Tg n = 
9/10, Tg n = 8/4. From the overall group, a subset of samples had reliable CD44 and CD62L 
staining and were used for analyses of those markers in brain 3.5 months non-Tg n = 5, Tg n 
= 3; 5 months: non-Tg n = 4, Tg n = 4; 7 months: non-Tg n = 5, Tg n = 5; 12 months: non-
Tg n = 6, Tg n = 4. Data was analyzed across genotypes and age with two-way analysis of 
variance (ANOVA). Sidak’s multiple comparisons test was used for post hoc comparisons 
within each age.
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Fig. 2. 
Altered naïve and effector T cell populations in deep cervical lymph nodes of 5xFAD mice. 
While there are no significant differences in DCLN in the number of CD4+ or CD8+ T cells 
(data not shown), there are significant changes within the CD4+ and CD8+ T cell 
populations. A) Tg mice show increased frequency of CD4+ naïve T cells, and decreased 
frequency of CD4+ effector T cells, significant difference at 5 months. DCLN CD4+ T cell 
subsets shift, with age, towards memory phenotypes. Frequency of both central and effector 
memory CD4+ T cells subsets are significantly increased at 12 months from 3.5, 5 and 7 
months, significant effect of age, no effect of genotype (data not shown). B) Tg mice show 
increased frequency of CD8+ naïve T cells, and decreased frequency of CD8+ Effector T 
cells, significant difference at 5 months. DCLN CD8+ T cell subsets shift, with age, towards 
memory phenotypes. Frequency of central memory CD8+ T cells are significantly increased 
at 12 months from 3.5, 5 and 7 months, significant effect of age, no effect of genotype (data 
not shown). Frequency of effector memory CD8+ T cells are significantly increased in non-
Tg mice as compared to Tg mice at 12 months of age, significant effect of age and of 
genotype (data not shown). 3.5 months: non-Tg n = 8, Tg n = 9; 5 months: non-Tg n = 11,Tg 
n = 11;7 months: non-Tg n = 11,Tg n = 13;12 months: non-Tg n = 10, Tg n = 9. Within 
these groups a subset of samples had reliable CD44 and CD62L staining and were used for 
analyses of those markers in DCLNs: 3.5 months non-Tg n = 5, Tg n = 3; 5 months: non-Tg 
n = 4, Tg n = 4; 7 months: non-Tg n = 5, Tg n = 5; 12 months: non-Tg n = 6, Tg n = 4 Data 
was analyzed across genotypes and age with two-way analysis of variance (ANOVA). 
Sidak’s multiple comparisons test was used for post hoc comparisons within each age.
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Fig. 3. 
Inhibition of soluble TNF with XPro1595 decreases populations of activated CD11b+ 
immune cells and CD4+ T cells in the brain of 5xFAD mice. Tg and non-Tg mice were 
treated with XPro1595 (10 mg/kg s.c.) twice weekly for two months either from 5 to 7 
months of age (A–E) or 2–4 months of age (F–H). A) Inhibition of soluble TNF with 
XPro1595 decreased MHCII+ populations within both activated (CD11b+ CD45high; 
frequency but not number) and quiescent (CD11b+ CD45low; frequency and number) 
immune cell populations, **p < 0.01; * p < 0.05. B) Ly6C, a marker of peripheral 
monocytes, displayed alterations with inhibition of soluble TNF. The ratio of 
Ly6Chigh:Ly6ClowCD11b+ brain immune cells in Tg mice is decreased, * p < 0.05. C) Brain 
T cells are decreased in frequency, but not number, with inhibition of soluble TNF, * p < 
0.05. D) Within the T cell population the number of CD4+ T cells is decreased with 
inhibition of soluble TNF with a trend towards decreased CD4+ effector T cells, * p < 0.05. 
E) There are no effects of soluble TNF inhibition on the CD8+ T cell population. F) 
Inhibition of soluble TNF from 2 to 4 months of age decreased the activated (CD45high) 
population and increased the quiescent (CD45low) population, * p < 0.05. G) There is a trend 
towards a decreased ratio of Ly6Chigh:Ly6ClowCD11b+ brain immune cells in Tg mice dosed 
from 2 to 4 months. H) No significant effects are seen in T cell populations at this age. 
Statistical analysis: significance was determined across treatment using non-parametric t-
test.
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Fig. 4. 
Inhibition of soluble TNF with XPro1595 increases the naïve T cell population in the deep 
cervical lymph nodes (DCLNs) of 5xFAD mice. There is no significant difference in the 
frequency or number of CD8+ (D) or CD4+ (A) T cells with in the DCLC following 
XPro1595 or saline treatment within genotype. B) Within the CD4+ T cell niche, the number 
but not frequency of naïve T cells is increased in Tg mice following inhibition of soluble 
TNF with XPro1595 as compared to saline treated Tg mice, * p < 0.05. C) The frequency of 
CD4+ effector T cells is unchanged in Tg mice following inhibition of soluble TNF with 
XPro1595 as compared to saline-treated Tg mice. No effects are seen on population cell 
counts or within the CD4+ central memory or effector memory populations. E) Within the 
CD8+ T cell niche, the frequency and count of naïve T cells is increased in Tg mice 
following inhibition of soluble TNF with XPro1595 as compared to saline treated Tg mice, * 
p < 0.05. F) The frequency but not count of effector T cells is decreased in Tg mice 
following inhibition of soluble TNF with XPro1595 as compared to saline treated Tg mice, * 
p < 0.05. No effects are seen on population cell counts or on the CD8+ central memory 
populations. Statistical analysis: significance was determined across treatment using non-
parametric t-test
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Fig. 5. 
Inhibition of soluble TNF with XPro1595 decreases amyloid beta in the subiculum and 
decreases pro-inflammatory mRNA in the hippocampus of 5xFAD mice. Amyloid-β (6E10) 
(A) and disintegration of multiple neuronal elements (measured by amino-cupric silver 
staining, NeuroScience Associates) (B) density was calculated in the hippocampus (yellow) 
and subiculum (dorsal: magenta; and ventral: green; posterior (when dorsal and ventral join): 
not shown) in saline- and XPro1595-treated Tg animals. A) No effect of soluble TNF 
inhibition was detected in the hippocampus; however, within the subiculum there was a 
significant reduction in amyloid burden specifically within the dorsal subiculum, * p < 0.5 
B) No significant effects for soluble TNF inhibition were detectable by amino-cupric sliver 
staining in either hippocampus or subiculum. C) Inhibition of soluble TNF decreases the 
expression of pro-inflammatory genes in Tg and non-Tg mice. CCL2 and TFGβ are 
significantly decreased in Tg mice, * p < 0.05. Statistical analysis: IHC data significance 
was determined across treatment using non-parametric t-test. qPCR mRNA data was 
normalized to non-tg saline and analyzed across genotypes and drug treatment conditions 
with two-way analysis of variance (ANOVA). Sidak’s multiple comparisons test was used 
for post hoc comparisons within genotype.
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Fig. 6. 
Inhibition of soluble TNF with peripheral XPro1595 administration in vivo rescued LTP 
impairment in 5xFAD mice. To determine if peripheral administration of XPro1595 
modulates synaptic function in Tg mice, brain slices were harvested for analysis of CA3-
CA1 synaptic strength curves (A (non-Tg); B (Tg)) and LTP levels (F (non-Tg); G (Tg)). At 
four months of age, basal synaptic strength deficits were relatively mild in saline-treated Tg 
mice, characterized by a modest downward shift in the synaptic strength curve and a 
significant reduction (p < 0.05) in the maximal EPSP/FV ratio, relative to non-Tg vehicle-
treated mice (C). XPro1595 had minimal effect on synaptic strength (A (non-Tg); B (Tg)), 
but it did slightly reduce and slightly increase the maximal EPSP/FV ratio in non-Tg and Tg 
mice, respectively (C). No genotype or XPro1595 treatment effects were observed for PPF 
measures (D) or population spike threshold (E). XPro1595 had more favorable effects for 
LTP deficits in Tg mice. LTP was induced in area CA1 using two 100 Hz stimulus trains 
(one second duration) separated by 10 s. Relative to vehicle-treated non-Tg mice, the Tg 
group showed a significant reduction in LTP levels (153.3 ± 9.5% vs 125.3 ± 5.7%, p < 
0.05) that was prevented by in vivo treatment with XPro1595 (158.2 ± 5.1%, p < 0.05 vs 
5xFAD vehicle group). In contrast, XPro1595 had minimal effect on LTP in non-Tg mice 
(141.4 ± 15.7%, H). Together, the results demonstrate that XPro1595 protects against LTP 
deficits in Tg mice. Synaptic strength parameters and LTP values were compared across 
genotypes and drug treatment conditions with two-way analysis of variance (ANOVA), 
Fisher’s PLSD was used for post hoc comparisons.
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Fig. 7. 
Specific targeting of sTNF/TNFR1 signaling rescues AD-like synaptic deficits and 
modulates AD-like associated immune cell population alterations. As Tg mice age, the brain 
becomes an inflamed environment with altered regulation of immune cell activation and 
peripheral immune cell trafficking to the CNS. While no evidence of peripheral 
inflammation is evident in plasma, there is evidence of altered T cell retention in the deep 
cervical lymph nodes to Tg mice, suggesting that the pro-inflammatory environment or 
potentially increased antigen presence is modulating peripheral immune cell populations. In 
vivo administration of peripheral XPro1595 to neutralize sTNF rescues LTP deficits and 
decreases amyloid (6e10) reactivity in the brain. These effects are associated with alterations 
in the brain inflammatory environment and immune cell traffic to the brain. In addition, 
XPro1595-treated group show further decrease in populations of activated CD11b+ immune 
cells as well as a decrease in CD4+ T cells suggesting these may be adaptive immune 
responses to the ongoing AD-like pathology.
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